Olpresan Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olpresan Plus, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients, often in combination with lifestyle modification. GNH USA supplies Olpresan Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olpresan Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olpresan Plus is an antihypertensive medication that acts on the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Essential hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Hypertension with fluid retention: provides added diuretic effect to reduce excess volume. - High‑risk cardiovascular patients: contributes to overall risk reduction when combined with other therapies.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance - Hepatic dysfunction

Before starting Olpresan Plus, patients should be evaluated for specific health conditions and monitored regularly.

- Renal impairment: adjust monitoring of kidney function and electrolytes. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte disorders: check serum potassium and sodium levels. - Pregnancy: avoid use, especially in the second and third trimesters. - Concomitant NSAIDs: increase risk of renal dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olpresan Plus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia. - Aliskiren (in diabetic patients): may cause excessive blood pressure reduction. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function. - ACE inhibitors or other ARBs: additive hypotensive effect. - Antidiabetic agents: may require dose adjustment due to blood pressure‑related glucose changes.